N-(5-((Aryl eller heteroaryl)methyloxy)pentyl)-substituerede iminosukre som inhibitorer af glucosylceramidsyntase

The present invention concerns D-deoxygalactonojirimycin derivatives shown below. These compounds display an increased inhibitory potency towards GCS, and/or an increased inhibitory potency towards GBA2, and/or a decreased inhibitory potency towards GBA1, relative to known deoxynojirimycin derivativ...

Full description

Saved in:
Bibliographic Details
Main Authors VAN BOECKEL, Stan, AERTS, Johannes Maria Franciscus Gerardus, VAN DEN BERG, Richard, GHISAIDOOBE, Amar, OVERKLEEFT, Herman Steven
Format Patent
LanguageDanish
Published 08.10.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention concerns D-deoxygalactonojirimycin derivatives shown below. These compounds display an increased inhibitory potency towards GCS, and/or an increased inhibitory potency towards GBA2, and/or a decreased inhibitory potency towards GBA1, relative to known deoxynojirimycin derivatives of the same D -galacto configuration. Therefore, compounds of the present invention are effective in the treatment of diseases which are associated with an irregular level of cytosolic or lysosomal glucosylceramide and/or higher glycosphingolipids, such as a lysosomal storage disorder, such as Gaucher disease, Fabry disease, Tay-Sachs disease, Sandhoff disease, GM1 gangliosidosis, Sialidosis, Niemann Pick disease type C and AMRF, or a symptom of one of the diseases collectively classed as metabolic syndrome, such as obesity, insulin resistance, hyperlipidemia, hypercholesterolemia, polycystic kidney disease, type II diabetes and chronic inflammation, or a neurodenegerative disorder, such as Parkinson disease or Lewy-body dementia.
Bibliography:Application Number: DK20150719845T